Samsung Biologics

207940.KO

680.68 USD

1.51

+0.22%

Overview

Last close

680.68 usd

Market cap

48.45B usd

52 week high

754.39 usd

52 week low

499.98 usd

Target price

706.1 usd

Valuation

P/E

N/A

Forward P/E

53.7634

Price/Sales

16.2923

Price/Book Value

6.4981

Enterprise Value

48.28B usd

EV/Revenue

15.7655

EV/EBITDA

34.621

Key financials

Revenue TTM

2.97B usd

Gross Profit TTM

1.03B usd

EBITDA TTM

1.34B usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

16,342.85B usd

Net debt

N/A usd

About

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the research and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates; and manufactures mammalian and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.